JP2023542932A5 - - Google Patents

Info

Publication number
JP2023542932A5
JP2023542932A5 JP2023518198A JP2023518198A JP2023542932A5 JP 2023542932 A5 JP2023542932 A5 JP 2023542932A5 JP 2023518198 A JP2023518198 A JP 2023518198A JP 2023518198 A JP2023518198 A JP 2023518198A JP 2023542932 A5 JP2023542932 A5 JP 2023542932A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
approximately
composition according
therapeutically effective
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542932A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/050677 external-priority patent/WO2022060987A1/en
Publication of JP2023542932A publication Critical patent/JP2023542932A/ja
Publication of JP2023542932A5 publication Critical patent/JP2023542932A5/ja
Pending legal-status Critical Current

Links

JP2023518198A 2020-09-18 2021-09-16 常染色体優性低カルシウム血症1型(adh1)の治療のためのトリフェニルカルシリティック化合物 Pending JP2023542932A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063080165P 2020-09-18 2020-09-18
US63/080,165 2020-09-18
US202163159397P 2021-03-10 2021-03-10
US63/159,397 2021-03-10
PCT/US2021/050677 WO2022060987A1 (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Publications (2)

Publication Number Publication Date
JP2023542932A JP2023542932A (ja) 2023-10-12
JP2023542932A5 true JP2023542932A5 (cg-RX-API-DMAC7.html) 2024-09-25

Family

ID=78087574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518198A Pending JP2023542932A (ja) 2020-09-18 2021-09-16 常染色体優性低カルシウム血症1型(adh1)の治療のためのトリフェニルカルシリティック化合物

Country Status (10)

Country Link
US (1) US20220087961A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213829A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542932A (cg-RX-API-DMAC7.html)
KR (1) KR20230112609A (cg-RX-API-DMAC7.html)
AU (1) AU2021343475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192684A1 (cg-RX-API-DMAC7.html)
IL (1) IL301409A (cg-RX-API-DMAC7.html)
MX (1) MX2023003129A (cg-RX-API-DMAC7.html)
TW (1) TW202227046A (cg-RX-API-DMAC7.html)
WO (1) WO2022060987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
WO2024220796A1 (en) * 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
CN116648243A (zh) * 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂

Similar Documents

Publication Publication Date Title
US7199157B2 (en) Use of treprostinil to improve kidney functions
JP6023734B2 (ja) 二次性副甲状腺機能亢進症の治療及び予防方法
EP2648737B1 (en) Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3
JP7177534B2 (ja) マカ組成物および使用方法
CN100531731C (zh) 谷氨酸盐、谷氨酸盐衍生物或代谢产物、谷氨酸盐类似物或其混合物在制备治疗骨质疏松症的组合物中的用途
US8481514B2 (en) Therapeutical uses of inecalcitol
WO2008058355A2 (en) Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
RU2586742C2 (ru) Композиция для лечения метаболических расстройств
JP3255926B2 (ja) 腎機能障害患者における燐酸塩過剰血症予防のための19−ノル−ビタミンd化合物の使用
US20260102370A1 (en) Methods of treating obesity in responder and non-responder populations
Brown et al. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism
US20100331286A1 (en) Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function
JP7344422B2 (ja) 糖尿病予防・治療用の医薬品組成物及びその用途
JP2021020917A (ja) サクビトリルおよびバルサルタンの組合せの新規使用
JP2731063B2 (ja) 卵巣欠落によるのぼせ治療剤
US20220347141A1 (en) Methods of treating phosphate concentration disorders with l-baiba
EP2162127A1 (en) Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists
JP2026515152A (ja) トリフェニルカルシリティック化合物を使用した副甲状腺機能低下症の治療
US10105375B2 (en) Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism
JP2023170339A (ja) 拡張型心筋症を処置または予防するための医薬組成物
WO2026088203A1 (en) Synergistic composition for poor muscle health and sarcopenia
WO2023081157A1 (en) Medium chain dicarboxylic acids for the treatment and prevention of diseases and conditions
Brown Vitamin D analogs for the treatment of secondary hyperparathyroidism in chronic renal failure
JP2007507479A (ja) 脂質代謝を調節するための方法および手段